In summary, this systematic review and NMA compared the efficacy and safety of lorlatinib and alectinib in ALK-p and ALK inhibitor-naïve NSCLC patients according to the best practice guidelines. The gene discussed is ALK; the disease is non-small cell lung carcinoma.